Pazopanib-induced posterior reversible encephalopathy syndrome with possible syndrome of i

Pazopanib-induced posterior reversible encephalopathy syndrome with possible syndrome of inappropriate secretion of antidiuretic hormone: an incidental or pathophysiological association? Jonathan Wong So; Bérenger Largeau; Frédérique Beau-Salinas; Stephan Ehrmann; Christophe Magni; Jér?me Meunier

【期刊名称】《中国神经再生研究（英文版）》

【年(卷),期】2020(015)006

【总页数】3

Introduction: Pazopanib is an oral protein kinase inhibitor (PKI)that targets vascular endothelial growth factor (VEGF) receptors,fibroblastic growth factor receptors, platelet-derived growth factor receptors, and stem cell factor that inhibits VEGF-induced cellular proliferation. Pazopanib is approved for use in advanced renal cell carcinoma and subtypes of advanced soft-tissue sarcoma (Deguchi et al., 2018). Major adverse drug reactions of pazopanib include hypertension, high-grade hyponatremia and posterior reversible encephalopathy syndrome (PRES) (Berardi et al., 2016; Deguchi et al., 2018).In clinical trials, few investigations have been conducted to determine the aetiology of PKI-associated hyponatremia, the mechanism remains therefore unknown. Only rare cases of PKI-induced syndrome of inappropriate secretion of antidiuretic hormone (SIADH)(Largeau et al., 2019), and none with